← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,877	+16	+0.9%	$155B
2	2 Amgen AMGN $238B	1,345	+4	+0.3%	$98.5B
3	3 Eli Lilly LLY $1.13T	1,118	-12	-1%	$61.2B
4	4 Becton Dickinson BDX $52.5B	932	+47	+5%	$25B
5	5 McKesson MCK $116B	926	+37	+4%	$44.8B
6	6 Teva Pharmaceutical Industries Limited TEVA $48B	822	0	0%	$32.5B
7	7 Conagra Brands CAG $6.81B	638	-10	-2%	$11.6B
8	8 Regeneron Pharmaceuticals REGN $82.5B	509	-3	-0.6%	$32.9B
9	9 Novo Nordisk NVO $174B	506	+5	+1%	$10.7B
10	10 DaVita DVA $11.9B	485	-11	-2%	$14.9B
11	11 AstraZeneca AZN $260B	386	-18	-4%	$6.15B
12	12 ResMed RMD $33.9B	326	+17	+6%	$5.27B
13	13 Accendra Health ACH $22M	233	+4	+2%	$2.07B
14	14 West Pharmaceutical WST $27B	214	-11	-5%	$4.05B
15	15 Herbalife HLF $1.52B	202	-40	-17%	$4.42B
16	16 Opko Health OPK $1.11B	191	+15	+9%	$1.14B
17	17 MannKind Corp MNKD $1.01B	184	+4	+2%	$552M
18	18 Dr. Reddy's Laboratories RDY $10.8B	174	+6	+4%	$1.41B
19	19 Tootsie Roll Industries TR $2.9B	161	+9	+6%	$466M
20	20 Fresenius Medical Care FMS $11.8B	140	-3	-2%	$489M
21	21 DELISTED WW International WW	133	-24	-15%	$393M
22	22 Alaunos Therapeutics TCRT $5.26M	128	+43	+51%	$737M
23	23 Medifast MED $136M	127	+3	+2%	$315M
24	ARNA 24 DELISTED Arena Pharmaceuticals Inc ARNA	122	-7	-5%	$612M
25	25 Lexicon Pharmaceuticals LXRX $725M	119	-4	-3%	$654M